ノロウイルス診断の世界市場

ノロウイルス診断の世界市場は2030年までに1億610万米ドルに達する見込み

2024年に6,900万米ドルと推定されるノロウイルス診断の世界市場は、分析期間2024-2030年にCAGR 7.4%で成長し、2030年には1億610万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである迅速検査キットは、CAGR 7.9％を記録し、分析期間終了までに6,830万米ドルに達すると予測されます。PCRキット分野の成長率は、分析期間中CAGR 5.9％と推定されます。

米国市場は1,810万米ドルと推定、中国はCAGR7.2％で成長予測

米国のノロウイルス診断市場は、2024年には1,810万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.2%として、2030年までに1,700万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.9％と6.2％と予測されています。欧州では、ドイツがCAGR 5.9%で成長すると予測されています。

世界のノロウイルス診断市場- 主要動向と促進要因まとめ

なぜヘルスケア現場でノロウイルス検査の需要が増加しているのか？

ノロウイルスは、世界的に最も一般的なウイルス性胃腸炎の原因の1つであり、あらゆる年齢層の人々が罹患しています。感染性が高いため、アウトブレイクはしばしば病院、長期介護施設、学校、クルーズ船で発生します。ヘルスケアシステムが感染の拡大を抑え、集団発生を効率的に管理することを目指す中で、タイムリーで正確な診断の必要性が高まっています。他の胃腸疾患とは異なり、ノロウイルスは汚染された表面、食品、水を通して急速に広がるため、早期の特定が重要となります。

現在では、特に施設環境において急性の下痢を呈する患者を対象に、ノロウイルス検査が日常的な診断に取り入れられています。臨床医は、ノロウイルスを細菌や他のウイルス感染と区別するための迅速で高感度なツールをますます必要としています。外来診療や救急現場での診断検査の採用が増加しているのは、臨床意識の高まりと感染制御プロトコルに対する規制の重点を反映しています。

スピードと精度を向上させる診断技術はどのように進化しているか？

技術の進歩により、従来の酵素免疫測定法から、より高い感度と特異性を提供する分子診断法へのシフトが進んでいます。便検体中のノロウイルスの遺伝子群の検出には、現在、リアルタイムPCRベースのアッセイやマルチプレックスパネルが広く使用されています。これらのプラットフォームは迅速な結果を提供するため、ヘルスケアプロバイダーはタイムリーな予防措置を講じ、適切なケアを開始することができます。

また、診療所や介護施設で分散的に使用するためのポイントオブケア検査機器も登場しており、集中的なラボを必要とせずに迅速な結果を得ることができます。アッセイ設計、サンプル調製、核酸増幅の改善により、低ウイルス量の信頼性の高い検出が可能になりつつあります。他の腸管病原体とともにノロウイルスを含む多重分子検査は、胃腸炎症例の診断を合理化するために、臨床ワークフローでますます好まれるようになっています。

どのような施設や公衆衛生の動向が検査の採用を拡大していますか？

病院、学校、高齢者ケアセンターなどの施設は、アウトブレイクの影響を軽減するために、ノロウイルスの日常的なスクリーニング・プロトコルに投資しています。公衆衛生機関は、リスクの高い環境で急性胃腸炎を管理するためのガイドラインを厳格化し、診断検査の頻度を高めています。検査室では、繁忙期やアウトブレイク時にノロウイルス検出のハイスループットを可能にする自動化システムの導入が進んでいます。

世界の旅行業界や外食産業も、食中毒や水系感染によって診断サーベイランスの需要が高まっていることから、その一翼を担っています。これに対応して、食品安全試験所や環境検査サービスは、コンプライアンスや品質管理基準を満たすためにノロウイルス検査法を取り入れています。遺伝子型の変異や発生源を追跡するサーベイランス・プログラムは、検査室で確認されたノロウイルス症例に大きく依存しており、診断学はさらに広範な疫学的モニタリング・システムに組み込まれています。

ノロウイルス診断市場の成長は、いくつかの要因によってもたらされます。

施設や地域社会におけるノロウイルス関連のアウトブレイク発生率の上昇が、迅速かつ正確な診断ツールに対する需要を押し上げています。リアルタイムPCRやマルチプレックス・プラットフォームなどの分子検査技術の向上により、検出速度と信頼性が向上しています。病院、長期介護施設、学校における感染制御プロトコルの実施が増加し、診断の一貫した使用が促進されています。ポイント・オブ・ケア検査とハイスループット・ラボ・プラットフォームの拡大が、アウトブレイクへの迅速な対応を支えています。食品安全および公衆衛生サーベイランスに対する規制の焦点は、ヘルスケア、環境、食品産業アプリケーションにおけるノロウイルス診断の採用をさらに促進しています。

セグメント

製品（迅速検査キット、PCRキット、ELISAベースキット）;エンドユース（病院エンドユース、診断ラボエンドユース、クリニックエンドユース）

調査対象企業の例

• Abbott Laboratories
• Abingdon Health
• Altona Diagnostics GmbH
• bioMerieux SA
• Becton, Dickinson and Company
• CerTest Biotec S.L.
• Danaher Corporation（Cepheid）
• DiaSorin S.p.A.
• ELITechGroup AG
• Eiken Chemical Co.
• Elisabeth Pharmacon
• Meridian Bioscience, Inc.
• Qiagen N.V.
• Quidel Corporation
• Roche Diagnostics（F. Hoffmann-La Roche Ltd.）
• Seegene Inc.
• Thermo Fisher Scientific, Inc.
• Luminex Corporation
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• GenMark Diagnostics, Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Norovirus Diagnostics Market to Reach US$106.1 Million by 2030

The global market for Norovirus Diagnostics estimated at US$69.0 Million in the year 2024, is expected to reach US$106.1 Million by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Rapid Test Kits, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$68.3 Million by the end of the analysis period. Growth in the PCR Kits segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.1 Million While China is Forecast to Grow at 7.2% CAGR

The Norovirus Diagnostics market in the U.S. is estimated at US$18.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.0 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Norovirus Diagnostics Market - Key Trends & Drivers Summarized

Why Is Demand for Norovirus Testing Increasing in Healthcare Settings?

Norovirus is one of the most common causes of viral gastroenteritis worldwide, affecting individuals across all age groups. Due to its high transmissibility, outbreaks often occur in hospitals, long-term care facilities, schools, and cruise ships. The need for timely and accurate diagnosis has increased as healthcare systems aim to reduce the spread of infection and manage outbreaks efficiently. Unlike other gastrointestinal illnesses, norovirus can spread quickly through contaminated surfaces, food, or water, making early identification critical.

Routine diagnostic practices now incorporate norovirus testing, especially for patients presenting with acute diarrhea in institutional settings. Clinicians increasingly require rapid, sensitive tools to differentiate norovirus from bacterial and other viral infections. The growing adoption of diagnostic testing in outpatient care and emergency settings reflects heightened clinical awareness and regulatory emphasis on infection control protocols.

How Are Diagnostic Technologies Evolving to Improve Speed and Accuracy?

Technological advancements are driving the shift from traditional enzyme immunoassays toward molecular diagnostics that offer greater sensitivity and specificity. Real-time PCR-based assays and multiplex panels are now widely used for detecting norovirus genogroups in stool samples. These platforms deliver rapid results, enabling healthcare providers to take timely preventive measures and initiate appropriate care.

Point-of-care testing devices are also emerging for decentralized use in clinics and care facilities, providing faster turnaround without the need for centralized labs. Improvements in assay design, sample preparation, and nucleic acid amplification are supporting reliable detection of low viral loads. Multiplex molecular tests that include norovirus along with other enteric pathogens are increasingly preferred in clinical workflows to streamline diagnosis in gastroenteritis cases.

What Institutional and Public Health Trends Are Expanding Testing Adoption?

Institutions such as hospitals, schools, and elder care centers are investing in routine norovirus screening protocols to reduce the impact of outbreaks. Public health agencies have implemented stricter guidelines for managing acute gastroenteritis in high-risk environments, contributing to more frequent diagnostic testing. Laboratories are adopting automated systems that allow high-throughput norovirus detection during peak seasons or in outbreak scenarios.

Global travel and food service industries also play a role, as foodborne and waterborne transmission drive demand for diagnostic surveillance. In response, food safety laboratories and environmental testing services are incorporating norovirus assays to meet compliance and quality control standards. Surveillance programs tracking genotypic variation and outbreak sources rely heavily on laboratory-confirmed norovirus cases, further integrating diagnostics into broader epidemiological monitoring systems.

Growth in the norovirus diagnostics market is driven by several factors.

Rising incidence of norovirus-related outbreaks in institutional and community settings is pushing demand for rapid and accurate diagnostic tools. Technological improvements in molecular testing, including real-time PCR and multiplex platforms, are enhancing detection speed and reliability. Increasing implementation of infection control protocols in hospitals, long-term care facilities, and schools is encouraging more consistent use of diagnostics. Expansion of point-of-care testing and high-throughput lab platforms is supporting faster outbreak response. Regulatory focus on food safety and public health surveillance is further driving adoption of norovirus diagnostics across healthcare, environmental, and food industry applications.

SCOPE OF STUDY:

The report analyzes the Norovirus Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Rapid Test Kits, PCR Kits, ELISA-based Kits); End-Use (Hospitals End-Use, Diagnostics Labs End-Use, Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• Abingdon Health
• Altona Diagnostics GmbH
• bioMerieux SA
• Becton, Dickinson and Company
• CerTest Biotec S.L.
• Danaher Corporation (Cepheid)
• DiaSorin S.p.A.
• ELITechGroup AG
• Eiken Chemical Co.
• Elisabeth Pharmacon
• Meridian Bioscience, Inc.
• Qiagen N.V.
• Quidel Corporation
• Roche Diagnostics (F. Hoffmann-La Roche Ltd.)
• Seegene Inc.
• Thermo Fisher Scientific, Inc.
• Luminex Corporation
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• GenMark Diagnostics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Norovirus Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Outbreak Frequency Drives Demand for Rapid Point-of-Care Norovirus Testing
  • Expansion of On-Site Molecular Diagnostic Capabilities Strengthens Infection Control Measures
  • Increased Use of PCR and Isothermal Amplification Techniques Enhances Detection Accuracy
  • Growing Focus on Food Safety Regulations Propels Adoption of Norovirus Screening Tools
  • Demand for Self-Contained Test Kits in Travel and Hospitality Sectors Accelerates Market Growth
  • Integration of Multiplex Panels Throws the Spotlight on Concurrent GI Pathogen Testing
  • Rising Awareness of Norovirus Transmission via Surface Contamination Generates Demand for Environmental Testing
  • Advancements in Biosensor and Microfluidics Technologies Support Portable Testing Solutions
  • Growth in Institutional and Healthcare Facility Testing Spurs New Contracting Opportunities
  • Rising Adoption of High-Throughput Lab Systems Expands Capacity for Mass Screening
  • Focus on Improved Sample Prep and Viral Concentration Methods Drives Sensitivity Improvements
  • Investment in At-Home Diagnostic Kits Encourages Decentralized Norovirus Testing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Norovirus Diagnostics Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Norovirus Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Norovirus Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Rapid Test Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Rapid Test Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for PCR Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for PCR Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for ELISA-based Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for ELISA-based Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Diagnostics Labs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Diagnostics Labs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 16: USA Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 17: USA 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 18: USA Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 19: USA 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Canada 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 22: Canada Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Canada 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• JAPAN
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 24: Japan Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Japan 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Japan 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• CHINA
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 28: China Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 29: China 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 30: China Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 31: China 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• EUROPE
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Norovirus Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe 6-Year Perspective for Norovirus Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Europe 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Europe 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• FRANCE
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: France 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 40: France Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 41: France 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• GERMANY
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 42: Germany Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Germany 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Germany 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• ITALY
  • TABLE 46: Italy Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Italy 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 48: Italy Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Italy 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• UNITED KINGDOM
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: UK 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 52: UK Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 53: UK 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Rest of Europe 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Rest of Europe 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• ASIA-PACIFIC
  • Norovirus Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Asia-Pacific 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Asia-Pacific 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Norovirus Diagnostics by Product - Rapid Test Kits, PCR Kits and ELISA-based Kits - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Rest of World 6-Year Perspective for Norovirus Diagnostics by Product - Percentage Breakdown of Value Sales for Rapid Test Kits, PCR Kits and ELISA-based Kits for the Years 2025 & 2030
  • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Norovirus Diagnostics by End-Use - Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Rest of World 6-Year Perspective for Norovirus Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostics Labs End-Use and Clinics End-Use for the Years 2025 & 2030

IV. COMPETITION